Full Press Release Details
MedTech Inc. Announces Closing of Merger to Acquire Precision Healing Inc.
WORTH, TX / April 4, 2022 / Sanara MedTech Inc. ("Sanara," the "Company," "we," "our"
or "us") (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving
patient outcomes, announced today that it has closed the previously announced merger to acquire Precision Healing Inc.
a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets, distributes and develops
wound and skincare products for use by physicians and clinicians in hospitals, clinics, and all post-acute care settings and offers wound
care and dermatology virtual consultation services via telemedicine. Sanara's products are primarily sold in the North American
advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX Surgical Activated
Collagen , FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix
to the surgical markets as well as the following products to the wound care market: BIAK S Antimicrobial Skin
and Wound Cleanser, BIAK S Antimicrobial Wound Gel, BIAK S Antimicrobial Skin and Wound
Irrigation Solution and HYCOL Hydrolyzed Collagen. Sanara's pipeline also contains potentially transformative
product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement,
and cell compatible substrates. The Company believes it has acquired the ability to drive its pipeline from concept to preclinical and
clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships
with a focus on products that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its
six focus areas of wound and skincare for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal,
hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of
the healthcare industry.
about Forward-Looking Statements
statements in this press release that do not constitute historical facts are "forward-looking statements," within the meaning
of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified
by terms such as "aim," "anticipates," "believe," contemplate," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential," "predicts,"
"preliminary," "project," "seek," "target," "should," "will"
or "would, or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements
include statements regarding, the development of new products, and expansion of the Company's business in telehealth and wound
care. These items involve risks, contingencies and uncertainties such as our ability to satisfy the closing conditions for and consummate
the merger on the expected timeline or at all, the ability to integrate and retain key personnel from Precision Healing, uncertainties
associated with the development and process for obtaining regulatory approval for new products, the extent of product demand, market
and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions,
and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual
operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of
these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities
Nichols, Director of Investor Relations